Supplements
Effectiveness scored 65 due to promising but limited small RCTs showing metabolic benefits primarily in low-baseline Akkermansia users (e.g., Depommier 2019: 10^10 CFU pasteurized improved insulin sensitivity 28.6% in 32 overweight participants; Zhang 2025: subgroup benefits on HbA1c/weight). Broader claims like weight loss/GLP-1 lack robust evidence. Safety high (90) as trials report no serious AEs, only transient GI upset; FDA no concerns despite NDI status. Quality 70 reflects lack of brand/t
Akkermansia supplements show moderate promise for metabolic support in overweight individuals with low gut levels, backed by small RCTs. Safe for most but start low to assess tolerance. Consider testing microbiome baseline; opt for pasteurized strains if available.